Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Hackensack UMC / John Theurer Cancer Center
mi
from
Hackensack, NJ
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Hackensack UMC / John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Adams Cancer Center
mi
from
Gettysburg, PA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Saint Francis Hospital
mi
from
Greenville, SC
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Avera Hematology and Transplant
mi
from
Sioux Falls, SD
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Avera Hematology and Transplant
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Associates in Oncology and Hematology
mi
from
Chattanooga, TN
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Associates in Oncology and Hematology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Sutter East Bay Hospitals
mi
from
Berkeley, CA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Sutter East Bay Hospitals
mi
from
Berkeley, CA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
City of Hope
mi
from
Duarte, CA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Midwestern Regional Medical Center
mi
from
Zion, IL
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Oncology Research-Park Nicollet Institute
mi
from
Saint Louis Park, MN
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Oncology Research-Park Nicollet Institute
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Saint Louis University
mi
from
Saint Louis, MO
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
York Cancer Center / Cancer Care Associates of York
mi
from
York, PA
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
York Cancer Center / Cancer Care Associates of York
mi
from
York, PA
Click here to add this to my saved trials
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated:  10/16/2017
Royal Hobart Hospital
mi
from
Hobart,
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status: Enrolling
Updated: 10/16/2017
Royal Hobart Hospital
mi
from
Hobart,
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Gulfcoast Oncology Associates
mi
from
Saint Petersburg, FL
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Gulfcoast Oncology Associates
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Wellstar-Northwest Georgia Oncology Centers
mi
from
Marietta, GA
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Wellstar-Northwest Georgia Oncology Centers
mi
from
Marietta, GA
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Chattanooga Oncology Hematology Care
mi
from
Chattanooga, TN
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Chattanooga Oncology Hematology Care
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated:  10/16/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma
Status: Enrolling
Updated: 10/16/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
Stanford Cancer Center
mi
from
Stanford, CA
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  10/17/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 10/17/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  10/17/2017
Rush University Medical Center
mi
from
Chicago, IL
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 10/17/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated:  10/18/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated: 10/18/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated:  10/18/2017
Clinical Research Facility
mi
from
Goshen, IN
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated: 10/18/2017
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated:  10/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated: 10/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated:  10/18/2017
Clinical Research Facility
mi
from
Fort Wayne, IN
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer
Status: Enrolling
Updated: 10/18/2017
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Peninsula Medical Center
mi
from
Burlingame, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Eden Medical Center
mi
from
Castro Valley, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Eden Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Mount Diablo Regional Cancer Center
mi
from
Concord, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Mount Diablo Regional Cancer Center
mi
from
Concord, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
North Bay Cancer Center
mi
from
Fairfield, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
North Bay Cancer Center
mi
from
Fairfield, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Marin Cancer Institute at Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Saint Rose Hospital
mi
from
Hayward, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Saint Rose Hospital
mi
from
Hayward, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated:  10/18/2017
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Status: Enrolling
Updated: 10/18/2017
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials